• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pharmather Hldgs Ltd (CSE: PHRM )

    0.2150 UNCHANGED
    Streaming Delayed Price Updated: 3:52 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.2150
    Bid (Size) 0.1750 (2,000)
    Ask (Size) 0.2200 (2,000)
    Prev. Close 0.2150
    Today's Range 0.2150 - 0.2150
    52wk Range 0.1050 - 0.4300
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -36.76%
    -36.76%
    1 Month
    N/A
    N/A
    3 Month
    -2.27%
    -2.27%
    6 Month
    +2.38%
    +2.38%
    1 Year
    +65.38%
    +65.38%

    More News

    Read More
    PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update for Expected FDA Approval of Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Holdings Provides Corporate Update
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.